Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors

摘要: Next generation sequencing (NGS) is becoming increasingly integrated into oncological practice and clinical research. NGS methods have also provided evidence for clonal evolution of cancers during disease progression treatment. The number variants associated with response to specific therapeutic agents keeps increasing. However, the identification novel driver mutations as opposed passenger (phenotypically silent or clinically irrelevant) remains a major challenge. We conducted targeted exome advanced solid tumors from 44 pre-treated patients including breast, colorectal lung carcinomas, neuroendocrine tumors, sarcomas others. catalogued established putative new drivers predicted by two distinct algorithms. we detected were consistent published observations. significant potential never described before in each tumor type studied. These belong key cell fate regulatory networks, potentially druggable pathways. Should our observations be confirmed, they would support hypothesis that are selected treatment aggressive indicate need longitudinal genomic testing inform second line cancer